Safety of rituximab in rheumatoid arthritis: A long-term prospective single-center study of gammaglobulin concentrations and infections

Joint Bone Spine

Volumn 79, Issue 4, 2012, Pages 365-369

  Isvy, Anne ^a   Meunier, Marine ^a   Gobeaux Chenevier, Camille ^a   Maury, Emilie ^a   Wipff, Julien ^a   Job Deslandre, Chantal ^a   Kahan, André ^a   Allanore, Yannick ^a,b  

^a AP HP université Paris Descartes ^*  (France)

^b INSTITUT COCHIN   (France)

Author keywords

Biotherapy; CD20; Infections; Rheumatoid arthritis; Rituximab

Indexed keywords

IMMUNOGLOBULIN; RITUXIMAB;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GAMMA-GLOBULINS; HEALTH STATUS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84863200671     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.12.004     Document Type: Article

References (26)

1. McInnes I.B., O'Dell J.R. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010, 69:1898-1906.
2. Edwards J.C., Cambridge G., Abrahams V.M. Do self-perpetuating B lymphocytes drive human autoimmune disease?. Immunology 1999, 97:188-196.
3. Edwards J.C., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001, 40:205-211.
4. Murawski N., Pfreundschuh M. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol 2010, 11:1074-1085.
5. Sibilia J., Gottenberg J.E., Mariette X. Rituximab: a new therapeutic alternative in rheumatoid arthritis. Joint Bone Spine 2008, 75:526-532.
6. Assous N., Gossec L., Dieudé P., et al. Rituximab therapy in rheumatoid arthritis in daily practice. J Rheumatol 2008, 35:31-34.
7. Gottenberg J., Ravaud P., Bardin T., et al. Risk factors of severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab (AIR) registry. Arthritis Rheum 2010, 62:2625-2632.
8. Popa C., Leandro M.J., Cambridge G., et al. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 years. Rheumatology 2007, 46:626-630.
9. Toussirot E., Pertuiset E., Sordet C., et al. Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice. Joint Bone Spine 2010, 77:142-145.
10. Castagnola E., Dallorso S., Faraci M., et al. Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy. J Hemato Ther Stem Cell Res 2003, 12:9-10.
11. Lim S.H., Esler W.V., Zhang Y., et al. B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk Lymphoma 2008, 49:152-153.
12. LimSH, ZhangY, WangZ, et al. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant 2005, 35:207-208.
13. Cattaneo C., Spedini P., Casari S., et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006, 47:1013-1017.
14. Askling J., Fored C.M., Brandt L., et al. Time-dependent increase in risk of hospitalization with infection among Swedish RA patients treated with TNF antagonist. Ann Rheum Dis 2007, 66:1339-1344.
15. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
16. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
17. Cohen S.B., Emery P., Greenwald M.W., et al. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating primary efficacy and safety at 24 weeks. Arthritis Rheum 2006, 54:2793-2806.
18. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose ranging trial. Arthritis Rheum 2006, 54:1390-1400.
19. Kelesidis T., Daikos G., Boumpas D., et al. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 2011, 15:2-16.
20. van Vollenhoven R.F., Emery P., Bingham C.O., et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010, 37:558-567.
21. Genovese M.C., Breedveld F.C., Emery P., et al. Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009, 68:1894-1897.
22. Keystone E., Fleischmann R., Emery P., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007, 56:3896-3908.
23. Zink A., Strangfeld A., Schneider M., et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006, 54:3399-3407.
24. Emery P., Deodhar A., Rigby W.F., et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (study evaluating rituximab's efficacy in MTX inadequate responders [SERENE]). Ann Rheum Dis 2010, 69:1629-1635.
25. Tak P.P., Rigby W.F., Rubbert-Roth A., et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011, 70:39-46.
26. Vital E.M., Rawstron A.C., Dass S., et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum 2011, 63:603-608.